HIF1AN Monoclonal Antibody

$25 ug total protein per lane of various lysates (see on figure) probed with HIF1AN monoclonal antibody, unconjugated (bsm-51675M) at 1:500 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.$

25 ug total protein per lane of various lysates (see on figure) probed with HIF1AN monoclonal antibody, unconjugated (bsm-51675M) at 1:500 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.

Applications

WB
ICC/IF

Reactivity

Human

Overview
Catalog #	bsm-51675m
Product Name	HIF1AN Monoclonal Antibody
Applications	WB ICC/IF
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Mouse
Source	KLH conjugated synthetic peptide derived from human HIF1AN
Immunogen Range	1-349/349
Clonality	Monoclonal
Clone #	L8U9
Concentration	0.5ug/ul
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	55662
Swiss Prot	Q9NWT6
Subcellular location	Nucleus
Synonyms	Hypoxia inducible factor asparagine hydroxylase; Factor inhibiting HIF1; FIH 1; FIH-1; FIH1; Hypoxia inducible factor 1 alpha inhibitor; Hypoxia inducible factor 1 alpha subunit inhibitor; Peptide aspartate beta dioxygenase; DKFZp762F1811; FLJ20615; FLJ22027; HIF1N_HUMAN.
Background	Hydroxylates HIF-1 alpha at 'Asp-803' in the C-terminaltransactivation domain (CAD). Functions as an oxygen sensor and,under normoxic conditions, the hydroxylation prevents interactionof HIF-1 with transcriptional coactivators includingCbp/p300-interacting transactivator. Involved in transcriptionalrepression through interaction with HIF1A, VHL and histonedeacetylases. Hydroxylates specific Asn residues within ankyrinrepeat domains (ARD) of NFKB1, NFKBIA, NOTCH1, ASB4, PPP1R12A andseveral other ARD-containing proteins. Also hydroxylates Asp andHis residues within ARDs of ANK1 and TNKS2, respectively.Negatively regulates NOTCH1 activity, accelerating myogenicdifferentiation. Positively regulates ASB4 activity, promotingvascular differentiation.
Application Dilution
WB	=1:500-2000
ICC/IF	ICC/IF=1:20-50